Cancer
Lung cancer in Guangzhou
广州 肺癌
17 hospitals in Guangzhou
Order: papers led on lung cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lung cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Guangzhou may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 357 papers led
- 236 papers led
- 186 papers led
- 83 papers led
- First Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院International Medical Center, Nansha campus71 papers ledNo open trial led
- 69 papers led
- 59 papers ledNo open trial led
- 41 papers ledNo open trial led
- 36 papers led
- 35 papers ledNo open trial led
- 28 papers ledNo open trial led
- 22 papers ledNo open trial led
- 13 papers led
- 5 papers ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
Lung cancer in every city Guangzhou on the disease page, with the national map
open trials on lung cancer with a hospital in Guangzhou
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Guangzhou as lead sponsor or study site. 96 of them are led by a hospital in Guangzhou. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Phase
- Phase 2/Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07063745
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Wuhan, Xiamen
- RecruitingA Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07103395
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingHS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01)
- Phase
- Phase 1
- Started
- 2026-08
- Posted
- Registry
- NCT07105176
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07195695
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wuhan, Xuzhou, Yangzhou, Zhengzhou
- RecruitingSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07222566
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
- RecruitingA Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07227025
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Harbin, Shanghai
- RecruitingA Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07227597
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jiangmen, Nanchang, Shanghai, Taizhou
- RecruitingA Phase II Study of SKB571 in Patients With Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07230405
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhengzhou
- RecruitingA Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07253142
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesFuzhou, Guangzhou, Harbin, Hefei, Nanning, Shanghai, Wuhan, Xinxiang, Xuzhou
- RecruitingSKB500 Combinations in Patients With Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07296809
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingAndamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07336732
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingElectro-Acupuncture in Lung cancER : EALER Study
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07337096
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou
- RecruitingPulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07348965
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07361497
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shantou, Shenzhen, Suzhou, Taiyuan, Taizhou, Xi'an, Zhengzhou
- RecruitingA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07361510
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shantou
- RecruitingA Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07367529
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Yangzhou, Zhongshan
- RecruitingA Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07412262
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Wuhan
- RecruitingPHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07416058
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingRC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07416474
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai
- RecruitingMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07431827
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang, Nanning, Shanghai, Shijiazhuang, Urumqi, Wuhan
- RecruitingA Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07444437
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Zhengzhou
- RecruitingPhase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07472478
Age 18 years to 80 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07472517
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Xuzhou, Yangzhou, Zhengzhou
- RecruitingBevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07481786
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesChongqing, Guangzhou
- RecruitingBeamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07486817
Age 18 years to Not stated (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingSymbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07489066
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingFulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07492342
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou
- RecruitingLarge Language Models Assist in Tumor MDT
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07504367
Age 25 years to 33 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingDownstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
- Phase
- Not given
- Started
- 2026-03
- Posted
- Registry
- NCT07528066
Age not stated (registered criteria)
Led by Shanghai Chest Hospital; 6 listed hospitals as study sitesFuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjin
- RecruitingA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07541170
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changchun, Chengdu, Foshan, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Shenzhen, Suzhou, Taizhou, Tianjin
- RecruitingRATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07541521
Age not stated (registered criteria)
Led by Shanghai Chest Hospital; 6 listed hospitals as study sitesFuzhou, Guangzhou, Nanjing, Qingdao, Shanghai, Shenzhen, Tianjin
- RecruitingA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07554339
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Shanghai, Shijiazhuang, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen
- RecruitingA Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
- Phase
- Phase 1/Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07559929
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
- Phase
- Phase 3
- Started
- 2026-08
- Posted
- Registry
- NCT07566052
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Hohhot, Nanchang, Nanning, Suzhou, Taiyuan
- RecruitingA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07586202
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin
- RecruitingAMT-116 in Combination With AK112 in Patients With Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07590531
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Hangzhou
- RecruitingHypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07609121
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07610798
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingSub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+Chemo
- Phase
- N/A
- Started
- 2026-05
- Posted
- Registry
- NCT07612722
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingA Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07622186
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Nanchang, Nanjing, Nanning, Shenyang, Taiyuan, Tianjin, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingEGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07637448
Age 18 years to Not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingA Study of HDM2020 in Patients With Advanced Sq-NSCLC
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07638891
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingPHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07645222
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingSCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07662395
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingEfficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07696832
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingBefotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07709585
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
- Phase
- Phase 2/Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07739186
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou
- RecruitingA Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)
- Phase
- Phase 2/Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07739199
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Wuhan
- RecruitingA Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-08
- Posted
- Registry
- NCT07739758
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shenyang
- RecruitingA Study of DS-3939a in Participants With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07739966
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Jinan, Shanghai, Taizhou, Tianjin, Wuhan, Zhengzhou
- RecruitingOral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
- Phase
- Phase 4
- Started
- 2026-06
- Posted
- Registry
- NCT07754812
Age 70 years to Not stated (registered criteria)
Led by Shanghai Pulmonary Hospital; 2 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai
- RecruitingAn Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07863167
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingMultimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07880106
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Posted
- Registry
- NCT06712355
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Shanghai, Shantou, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
- RecruitingThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06758401
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingAssociation Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06771960
Age 18 years to 80 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingA Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-02
- Posted
- Registry
- NCT06792552
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang
- RecruitingA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT06793215
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nantong, Shanghai, Shantou, Wuhan
- RecruitingStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06801834
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Shanghai, Shenzhen, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xinxiang, Yangzhou, Zhengzhou
- RecruitingClinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06809764
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Wuhan, Xiamen, Zhengzhou
- RecruitingA Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
- Phase
- Phase 1
- Started
- 2025-02
- Posted
- Registry
- NCT06839105
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanchang, Shanghai, Shenyang, Wuhan
- RecruitingA Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
- Phase
- Phase 1
- Started
- 2025-04
- Posted
- Registry
- NCT06858813
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingReal World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT06862869
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Lanzhou, Nanchang, Nanjing, Nantong, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Wuxi, Xi'an, Yinchuan, Zhanjiang, Zunyi
- RecruitingEvaluation of JSKN016 Combination Therapy in Subjects With NSCLC
- Phase
- Phase 1
- Started
- 2025-04
- Posted
- Registry
- NCT06868732
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06875310
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou
- RecruitingStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06890598
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesAnyang, Beijing, Changsha, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang, Nanning, Shanghai, Shantou, Shenzhen, Suzhou, Taizhou, Tianjin, Wuhan, Xi'an
- RecruitingA Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06892548
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Xi'an, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yichang, Zhengzhou
- RecruitingStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT06899126
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou
- RecruitingPostoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC(ARMOR2501)
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06924398
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingNeoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06926790
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingA Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06930794
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou
- RecruitingAn Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT06942143
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
- Phase
- Phase 1
- Started
- 2025-06
- Posted
- Registry
- NCT06946927
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingA Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06962865
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Linyi, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Yantai, Zhengzhou
- RecruitingPROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06977074
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07005102
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Wuhan
- RecruitingOmitting CTV for Primary Tumor in LS-SCLC
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07008716
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07010263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi
- RecruitingZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07038096
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingToripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT07039656
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingHypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07052669
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteChongqing, Guangzhou
- RecruitingStudy of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07079475
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanjing, Shanghai, Shenyang, Tianjin
- RecruitingCombination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07086456
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07111520
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xiangyang, Xinxiang, Xuzhou, Yangzhou
- RecruitingAdaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07120698
Age 28 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07143045
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesChangchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shenyang, Shenzhen, Taiyuan, Tianjin, Wuhan, Xiamen, Yangzhou, Zhengzhou
- RecruitingA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07144280
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingPhase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07154706
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Jinan, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07155187
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Nanchang, Shanghai, Urumqi
- RecruitingA Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07164170
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07169994
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang
- RecruitingA Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07174908
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou
- RecruitingPhase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07175220
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07178795
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingSequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07181499
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhuhai
- RecruitingA Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07182682
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07185997
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou
- RecruitingA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT07190248
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingIBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07198841
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Foshan, Guangzhou, Nanchang, Nanning, Shijiazhuang
- RecruitingA Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07208773
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07217301
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luzhou, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Xi'an, Xinxiang, Xuzhou, Zhengzhou
- RecruitingA Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07218146
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingSymbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07226999
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingA Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07229729
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2025-11
- Posted
- Registry
- NCT07232420
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07241767
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingNeoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07309952
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07375316
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Shantou, Shenzhen
- RecruitingA Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
- Phase
- Phase 1
- Started
- 2025-10
- Posted
- Registry
- NCT07381829
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingPhase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07534033
Age 18 years to 80 years (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingMultimodal AI-Guided Recovery Management After Lung Cancer Surgery
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT07588737
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingStudy on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07610616
Age 18 years to 100 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingEvaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLC
- Phase
- N/A
- Started
- 2025-12
- Posted
- Registry
- NCT07626736
Age 18 years to Not stated (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingPD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
- Phase
- Not given
- Started
- 2025-10
- Posted
- Registry
- NCT07775820
Age 18 years to Not stated (registered criteria)
Led by Nanfang Hospital; 4 listed hospitals as study sitesGuangzhou, Nanchang, Shenzhen, Wenzhou
- RecruitingA Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT05956587
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Luoyang, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Phase
- Phase 2
- Started
- 2024-02
- Posted
- Registry
- NCT06172478
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou
- RecruitingA Study of ZL-1310 in Subjects With Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06179069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Shanghai, Shenyang, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingGPC3/Mesothelin-CAR-γδT Cells Against Cancers
- Phase
- Phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06196294
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingA Study of HLX42 in Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2024-03
- Posted
- Registry
- NCT06210815
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingShort-term Effects of Preoperative Exercise in Moderate-to-high Perioperative Risk Lung Cancer Patients
- Phase
- N/A
- Started
- 2024-01
- Posted
- Registry
- NCT06215326
Age 18 years to Not stated (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingThe Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis
- Phase
- N/A
- Started
- 2024-03
- Posted
- Registry
- NCT06244264
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingNeoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06269211
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 1 listed hospital as study siteGuangzhou, Shanghai
- RecruitingD-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06300177
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- RecruitingIntra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
- Phase
- N/A
- Started
- 2024-04
- Posted
- Registry
- NCT06304441
Age 18 years to 75 years (registered criteria)
Led by Third People's Hospital, Guangzhou Medical UniversityGuangzhou
- RecruitingA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Phase
- Phase 3
- Started
- 2024-04
- Posted
- Registry
- NCT06312137
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Taizhou, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06345729
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Suzhou, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Zhengzhou
- RecruitingNeoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06383728
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingJAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06416410
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Wuxi, Xi'an, Zhengzhou
- RecruitingPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Phase
- Phase 3
- Started
- 2024-06
- Posted
- Registry
- NCT06422143
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanchang, Shanghai, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen, Yangzhou, Zhengzhou
- RecruitingctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06426511
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingPD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06429696
Age 18 years to 75 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06452277
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Shanghai, Taizhou, Wuhan, Xiamen
- RecruitingA Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
- Phase
- Phase 1
- Started
- 2024-06
- Posted
- Registry
- NCT06461156
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06465069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06475300
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingInterventional Software for Multi-immunotherapy of Solid Tumors
- Phase
- Phase 2/Phase 3
- Started
- 2024-04
- Posted
- Registry
- NCT06478108
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingCheckpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06483347
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingNeoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06492421
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingA Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06496490
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin, Jiangmen, Nanchang, Nanning, Shanghai, Tianjin, Xi'an, Zhengzhou, Zunyi
- RecruitingMaintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06497530
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingStudy of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06514027
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingBefotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06517953
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingDifferentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
- Phase
- Not given
- Started
- 2024-06
- Posted
- Registry
- NCT06518655
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Foshan, Guangzhou, Shanghai, Wuhan
- RecruitingIdentification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
- Phase
- Not given
- Started
- 2024-06
- Posted
- Registry
- NCT06528418
Age 18 years to 100 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingElimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06542159
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Phase
- Phase 3
- Started
- 2024-10
- Posted
- Registry
- NCT06561386
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Xinxiang
- RecruitingNeoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06563999
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- Phase
- Phase 3
- Started
- 2024-11
- Posted
- Registry
- NCT06564324
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingTransthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
- Phase
- N/A
- Started
- 2024-09
- Posted
- Registry
- NCT06572540
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Shanghai, Zhengzhou
- RecruitingVebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06574347
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingElimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06582940
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingStereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study
- Phase
- Phase 3
- Started
- 2024-10
- Posted
- Registry
- NCT06598527
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingEfficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06607796
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingA Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06667908
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingA Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China
- Phase
- Not given
- Started
- 2024-09
- Posted
- Registry
- NCT06718972
Age not stated (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingConcurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06719700
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingEfficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06728852
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingElimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06730295
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingNeoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06734182
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingNeoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2024-11
- Posted
- Registry
- NCT06734702
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06775275
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingEstablishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
- Phase
- Not given
- Started
- 2024-01
- Posted
- Registry
- NCT06843707
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingStudy of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06911606
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingA Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
- Phase
- Phase 3
- Started
- 2024-09
- Posted
- Registry
- NCT06970639
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingThe Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening
- Phase
- N/A
- Started
- 2024-07
- Posted
- Registry
- NCT06988579
Age 40 years to 74 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingEarly Intervention Strategies for Lung Cancer
- Phase
- N/A
- Started
- 2024-06
- Posted
- Registry
- NCT06988943
Age 40 years to 74 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingD-BACE in Combination With Chemotherapy and Camrelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT07016126
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingValidation of High-Throughput Large-Format Tissue Preprocessing for Lung and Colorectal Cancer
- Phase
- Not given
- Started
- 2024-10
- Posted
- Registry
- NCT07239063
Age not stated (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingSugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
- Phase
- Phase 2/Phase 3
- Started
- 2023-07
- Posted
- Registry
- NCT05623267
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingSavolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression
- Phase
- Phase 1/Phase 2
- Started
- 2023-07
- Posted
- Registry
- NCT05777278
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingNeoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
- Phase
- Phase 2
- Started
- 2023-04
- Posted
- Registry
- NCT05800340
Age 18 years to Not stated (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingAdjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients
- Phase
- Phase 2
- Started
- 2023-04
- Posted
- Registry
- NCT05825443
Age 18 years to 80 years (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05920356
Age 18 years to 100 years (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingA Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT05989542
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingExploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
- Phase
- Not given
- Started
- 2023-08
- Posted
- Registry
- NCT05997719
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06010329
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou
- RecruitingPhase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT06095583
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Yinchuan, Zhengzhou
- RecruitingA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06119581
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiangyang, Yichang, Zhanjiang
- RecruitingSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06170788
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Shanghai, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Xiangyang, Xuzhou, Zhanjiang, Zhengzhou
- RecruitingEffects of Digital Therapeutic in Whole Process Management of Lung Cancer
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT06230445
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingEfficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery
- Phase
- N/A
- Started
- 2023-09
- Posted
- Registry
- NCT06286150
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2022-03
- Posted
- Registry
- NCT04928846
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05168566
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Linyi, Nanjing, Shanghai, Shenyang, Wuhan, Zhengzhou
- RecruitingPhase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Phase
- Phase 1/Phase 2
- Started
- 2022-04
- Posted
- Registry
- NCT05288205
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Harbin, Hefei, Hohhot, Jinan, Linyi, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou
- RecruitingFurmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
- Phase
- Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05334277
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangchun, Chengdu, Foshan, Guangzhou, Hangzhou, Jiangmen, Nanchang, Shenyang, Urumqi, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingEGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
- Phase
- Early phase 1
- Started
- 2022-05
- Posted
- Registry
- NCT05341492
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingSKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
- Phase
- Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05351788
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingEfficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients
- Phase
- N/A
- Started
- 2022-06
- Posted
- Registry
- NCT05378334
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingAdjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
- Phase
- Not given
- Started
- 2022-08
- Posted
- Registry
- NCT05457049
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesFoshan, Guangzhou, Shantou, Zhongshan
- RecruitingA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2022-11
- Posted
- Registry
- NCT05498428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Harbin, Shanghai, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai
- RecruitingAdjuvant Treatment Based on MRD for EGFR Mutant NSCLC
- Phase
- Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05536505
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei, Qingdao, Shanghai, Shenzhen, Wuhan, Xiamen, Zhongshan
- RecruitingRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05579366
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan
- RecruitingPhase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
- Phase
- Phase 1
- Started
- 2022-05
- Posted
- Registry
- NCT06128148
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingPulmonary Watershed Topographic Map Navigation for Lung Nodule Resection
- Phase
- N/A
- Started
- 2022-01
- Posted
- Registry
- NCT06404164
Age not stated (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingStudy of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2022-04
- Posted
- Registry
- NCT06706713
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Guangzhou
- RecruitingA Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
- Phase
- Phase 1/Phase 2
- Started
- 2022-10
- Posted
- Registry
- NCT07231068
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Zhengzhou
- RecruitingEngineered TILs/CAR-TILs to Treat Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2021-01
- Posted
- Registry
- NCT04842812
Age 18 years to 85 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingBeamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Phase
- Phase 1
- Started
- 2021-07
- Posted
- Registry
- NCT04886804
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou
- RecruitingStudy of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Posted
- Registry
- NCT04930432
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
- RecruitingIntratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2021-03
- Posted
- Registry
- NCT04952272
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingMRD Monitoring in Lung Cancer After Resection
- Phase
- Not given
- Started
- 2021-09
- Posted
- Registry
- NCT04976296
Age 18 years to Not stated (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingEarly Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients
- Phase
- Phase 3
- Started
- 2021-06
- Posted
- Registry
- NCT04980716
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingNeoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
- Phase
- Phase 2
- Started
- 2021-08
- Posted
- Registry
- NCT05011487
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingPhase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Posted
- Registry
- NCT05024214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Shanghai, Shenyang, Taiyuan, Tianjin, Zhengzhou, Zhuhai
- RecruitingTriplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Posted
- Registry
- NCT05187338
Age 18 years to 70 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingA Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
- Phase
- Phase 3
- Started
- 2020-07
- Posted
- Registry
- NCT04316364
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Zhengzhou
- RecruitingStudy of PF-07248144 in Advanced or Metastatic Solid Tumors
- Phase
- Phase 2
- Started
- 2020-11
- Posted
- Registry
- NCT04606446
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Xi'an
- RecruitingPhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Phase
- Phase 2/Phase 3
- Started
- 2020-12
- Posted
- Registry
- NCT04613596
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingNeoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
- Phase
- Phase 2
- Started
- 2019-03
- Posted
- Registry
- NCT03872661
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingAPG-2449 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2019-05
- Posted
- Registry
- NCT03917043
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Wuhan
- RecruitingAssessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2019-07
- Posted
- Registry
- NCT04270591
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Zhengzhou
- RecruitingThe Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
- Phase
- Not given
- Started
- 2019-05
- Posted
- Registry
- NCT04286841
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingStudy of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC
- Phase
- Early phase 1
- Started
- 2019-09
- Posted
- Registry
- NCT05060796
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingLcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
- Phase
- Not given
- Started
- 2019-06
- Posted
- Registry
- NCT06778512
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Phase
- Phase 1
- Started
- 2018-04
- Posted
- Registry
- NCT03460977
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Nanjing, Wenzhou
- RecruitingTrans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
- Phase
- Phase 2/Phase 3
- Started
- 2018-11
- Posted
- Registry
- NCT03755739
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingEvaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC
- Phase
- N/A
- Started
- 2018-11
- Posted
- Registry
- NCT03769129
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingTCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2018-12
- Posted
- Registry
- NCT03778814
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingiCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray
- Phase
- Not given
- Started
- 2017-07
- Posted
- Registry
- NCT03192501
Age 18 years to 70 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingGPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers
- Phase
- Phase 1
- Started
- 2017-07
- Posted
- Registry
- NCT03198052
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical University; 1 listed hospital as study siteGuangzhou
- RecruitingGPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
- Phase
- Phase 1
- Started
- 2017-07
- Posted
- Registry
- NCT03198546
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical University; 1 listed hospital as study siteGuangzhou
- RecruitingNon-risk Based Lang Cancer Screening With a One-off LDCT
- Phase
- N/A
- Started
- 2015-12
- Posted
- Registry
- NCT04938804
Age 40 years to 74 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingA Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
- Phase
- Not given
- Started
- 2012-09
- Posted
- Registry
- NCT01994057
Age 18 years to 85 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingGolidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07303881
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingNK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
- Phase
- Phase 1
- Started
- 2026-01
- Posted
- Registry
- NCT07318636
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingA Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07318883
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingA Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07338396
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Guangzhou
- Not yet recruitingStudy on the Effectiveness and Safety of CLE Combined With Cryobiopsy for Diagnosis of Pulmonary Lesions
- Phase
- N/A
- Started
- 2026-02
- Posted
- Registry
- NCT07352176
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingNon-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07395375
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingTubeless Strategy for Enhanced Recovery After Sublobar Resection
- Phase
- N/A
- Started
- 2026-02
- Posted
- Registry
- NCT07409129
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingLimertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07413952
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingGFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07554859
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingSelective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer (SCIENCE Study)
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07617389
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingManagement Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC
- Phase
- Not given
- Started
- 2026-08
- Posted
- Registry
- NCT07674524
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA Phase 2 Study of ABSK043 Combined With Osimertinib
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07710612
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesGuangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Taiyuan, Wuhan
- Not yet recruitingMicrobiota in Neoadjuvant Chemoimmunotherapy for NSCLC
- Phase
- Not given
- Started
- 2026-07
- Posted
- Registry
- NCT07752589
Age 18 years to 80 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingPaclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07819591
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07827261
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingLocal Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07842471
Age 18 years to Not stated (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingA Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2026-11
- Posted
- Registry
- NCT07865910
Age 18 days to 75 days (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesAnyang, Beijing, Chongqing, Guangzhou, Jinan, Nanning, Qingdao, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou, Zunyi
- Not yet recruitingProspective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLC
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07874464
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingSHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study
- Phase
- Phase 3
- Started
- 2026-11
- Posted
- Registry
- NCT07895992
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingMRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer
- Phase
- Early phase 1
- Started
- 2025-01
- Posted
- Registry
- NCT06735508
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingStudy of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06885840
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Foshan, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingA Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT06963502
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Hangzhou
- Not yet recruitingA Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07038460
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangsha, Guangzhou, Hangzhou
- Not yet recruitingA Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07103408
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingIparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07129161
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Xi'an
- Not yet recruitingNebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07150416
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingAK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07158840
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingA Real-World Study of IBI351 for KRAS G12C+ NSCLC in China
- Phase
- Not given
- Started
- 2025-10
- Posted
- Registry
- NCT07198620
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingMyeloprotection With Trilaciclib in Pan-cancer Population
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06297811
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingA Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy
- Phase
- N/A
- Started
- 2024-06
- Posted
- Registry
- NCT06422637
Age 40 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- Not yet recruitingClinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
- Phase
- Phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT06585059
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingMinimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
- Phase
- N/A
- Started
- 2024-11
- Posted
- Registry
- NCT06709274
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Chengdu, Foshan, Guangzhou, Nanjing, Nantong, Shenzhen, Wuhan
- Not yet recruitingYK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- Phase
- Phase 3
- Started
- 2023-05
- Posted
- Registry
- NCT05767892
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingA Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05990127
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou
- Enrolling by invitationEfficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06281964
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Enrolling by invitationEfficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
- Phase
- Phase 3
- Started
- 2021-08
- Posted
- Registry
- NCT04762459
Age 18 years to 130 years (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Guangzhou
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Brain Hospital of Guangzhou Medical University广州医科大学附属脑科医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Affiliated Cancer Hospital of Guangzhou Medical University广州医科大学附属肿瘤医院 | 291 open | 1 | 31 | 18 | 28 | none | 30 | 15 | none | none | none | 0 | none | 1 | 0 | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Affiliated Hospital of Southern China University of Technology华南理工大学医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Affiliated Hospital, Sun Yat-sen University中山大学附属口腔医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Air Force Hospital中国人民解放军南部战区空军医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Children Hospital广东省妇幼保健院 | none | none | none | none | none | none | 13 | none | none | none | none | 1 | none | 0 | 1 | none | none | none | none | none | 7 | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | 2 | none | none | none | none | none | none | none | |
| Children's Medical Center广州医科大学附属妇女儿童医疗中心 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | |
| Clifford Hospital | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Dermatology Hospital上海市皮肤病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | 1 | none | none | none | none | none | none | |
| Dermatology Hospital, Southern Medical University南方医科大学皮肤病医院、广东省皮肤病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | |
| Eighth People's Hospital of Guangzhou Affiliated to Guangzhou Medical College广州医科大学附属市八医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fifth Affiliated Hospital of Guangzhou Medical University广州医科大学附属第五医院 | 1 | 5 | none | none | 22 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Fifth Affiliated Hospital of Southern Medical University南方医科大学第五附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Guangdong Pharmaceutical University广东药科大学附属第一医院 | 4 | none | none | none | none | none | none | none | none | none | none | 0 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院 | 6 | 3 | none | none | 18621 open | none | none | none | none | none | none | 0 | none | 1 | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | 0 | 0 | none | 21 | 3 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | 0 | none | none | none | none | |
| First Affiliated Hospital of Guangzhou University of Chinese Medicine广州中医药大学第一附属医院 | 2 | none | 32 | 12 | 35 | none | 4 | none | none | none | none | 2 | none | none | none | 2 | none | none | none | 7 | 0 | 0 | none | none | none | none | none | 6 | none | none | none | 4 | none | none | none | 1 | none | 4 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Jinan University暨南大学附属第一医院 | 16 | 5 | 451 open | 21 | 59 | none | 57 | 30 | none | 0 | none | 9 | 1 | 2 | none | 5 | none | none | none | 5 | 2 | none | none | none | none | none | none | 4 | none | 2 | none | 7 | 6 | none | 0 | none | none | 1 | none | none | none | none | none | none | none | 1 | 0 | none | none | none | none | none | none | 2 | 2 | none | none | none | none | none | none | |
| First Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院 | 143 open | 201 open | 2196 open | 52 | 71 | 39 | 491 open | 391 open | 5 | 1 | 0 | 33 | 92 open | 0 | 1 | 18 | 1 | none | 2 | 3 | 5 | none | none | none | none | 2 | none | 28 | 4 | 6 | 12 | 211 open | 61 open | 5 | 2 | 0 | 1 | 9 | none | 2 | 4 | 0 | 0 | 5 | 4 | 0 | 222 open | 0 | none | none | 1 | 0 | none | 1 | none | 0 | 0 | none | none | none | none | |
| Fuda Cancer Hospital广州复大肿瘤医院 | 0 | none | 0 | 0 | 0 | 0 | 0 | 0 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangdong Clifford Hospital广东祈福医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangdong Province Hospital for Occupational Disease Prevention and Treatment广东省职业病防治院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangdong Provincial Hospital of Chinese Medicine广东省中医院 | 5 | none | 25 | 12 | 41 | 6 | 501 open | 12 | none | none | none | 2 | 1 | 3 | 1 | none | none | none | none | none | 0 | none | none | none | none | 4 | none | 0 | none | none | none | 15 | 7 | none | 0 | none | none | 2 | 1 | 4 | none | none | none | none | none | none | 6 | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | |
| Guangdong Provincial People's Hospital广东省人民医院 | 14 | 19 | 541 open | 211 open | 23619 open | 441 open | 9610 open | 43 | 1 | 2 | 1 | 11 | 1 | 0 | none | 3 | 1 | none | none | 23 | 1 | none | none | none | none | 3 | 3 | 1 | none | none | none | 652 open | 80 | none | none | 0 | none | 2 | none | 1 | none | 1 | none | none | 1 | none | 81 open | none | none | none | 4 | 1 | none | none | none | none | none | none | none | none | none | |
| Guangdong Provincial Second Hospital广东省第二中医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangdong Second Provincial General Hospital广东省第二人民医院 | 3 | none | 16 | none | none | none | none | none | none | none | none | 2 | none | 1 | none | 31 open | none | none | 2 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | 1 | none | 1 | none | none | none | 1 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Chest Hospital广州市胸科医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Dongsheng Hospital广州市东升医院(广州市老年病康复医院) | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Eighth People's Hospital广州市第八人民医院(嘉禾院区) | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | |
| Guangzhou First People's Hospital广州市第一人民医院 | 4 | none | 22 | 12 | none | 11 | 20 | none | none | none | none | 4 | 0 | 1 | none | 0 | none | 13 | none | 7 | 1 | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | 4 | 1 | none | 2 | none | none | none | none | none | 2 | none | none | 1 | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou General Hospital中国人民解放军南部战区总医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 0 | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Hospital广州市中西医结合医院 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Orthopedics Hospital广州市正骨医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Panyu Central Hospital广州医科大学附属番禺中心医院 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Red Cross Hospital广州市红十字会医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | |
| Guangzhou Women and Children's Medical Center广州市妇女儿童医疗中心 | 2 | none | none | none | 5 | none | 161 open | 13 | 9 | 3 | none | 1 | 0 | 321 open | none | none | 21 open | none | none | none | 191 open | 0 | none | none | none | 1 | none | none | none | 2 | 19 | 7 | 34 | 2 | 3 | none | none | 1 | none | 0 | none | none | 1 | 2 | none | 2 | 0 | 1 | none | 1 | none | 0 | 11 | 7 | none | none | none | none | none | none | none | |
| Hexian Memorial Hospital广州市番禺区妇幼保健院 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | |
| Huadu Distinct People's Hospital广州市花都区人民医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Integrated Hospital, Southern Medical University南方医科大学中西医结合医院 | 7 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Nanfang Hospital南方医科大学南方医院 | 336 open | 84 open | 1277 open | 12812 open | 835 open | 8 | 832 open | 531 open | 0 | 0 | none | 6 | 2 | 2 | none | 3 | 8 | none | none | 19 | 21 | 9 | 1 | none | none | 3 | none | 1 | 6 | none | none | 13 | 1 | 0 | 7 | none | none | 5 | none | 6 | 1 | 2 | none | 0 | none | 0 | 51 open | none | none | none | 1 | none | 1 | 0 | none | none | 2 | none | none | none | none | |
| Panyu Hospital广州市番禺区中医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Affiliated Hospital of Guangzhou Medical University广州医科大学附属第二医院 | 4 | none | 3918 open | 41 open | 1315 open | 64 open | 84 open | 14 | none | none | none | 1 | none | 1 | none | 5 | 0 | none | none | 2 | 2 | 0 | none | none | none | 2 | none | none | none | none | none | none | 4 | none | 0 | none | none | 3 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | |
| Sixth Affiliated Hospital of Guangzhou Medical University清远市人民医院 | 3 | none | none | none | none | none | none | 12 | none | none | none | 2 | none | none | none | none | none | none | none | none | 1 | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Sixth Affiliated Hospital of Sun Yat-sen University中山大学附属第六医院 | none | 0 | none | 455 open | none | 7 | 161 open | none | none | 0 | none | 1 | 3 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 4 | 1 | none | none | none | 1 | none | 0 | 1 | none | 0 | none | none | none | none | |
| Sun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院 | 255 open | 102 open | 6610 open | 115 open | 362 open | 34 | 13548 open | 11 | 2 | none | none | 6 | 0 | 101 open | 2 | 1 | 4 | none | 4 | 7 | 6 | none | none | none | none | 01 open | 4 | none | none | none | none | 29 | 2 | 4 | none | none | 1 | none | none | 3 | none | none | none | none | 1 | none | 7 | none | none | 0 | 0 | 0 | none | none | none | none | none | none | none | none | none | |
| Sun Yat-sen University Cancer Center中山大学肿瘤防治中心 | 48357 open | 1378 open | 28118 open | 1034 open | 35732 open | 553 open | 22217 open | 621 open | 01 open | none | 0 | 191 open | 2 | 75 open | 31 open | 16 | 3 | none | 1 | 14225 open | 1 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Third Affiliated Hospital of Guangzhou Medical University广州医科大学附属第三医院 | 4 | none | none | none | none | 20 | none | none | none | none | none | 4 | none | 0 | none | none | none | none | none | none | 5 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 1 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | |
| Third Affiliated Hospital of Guangzhou University of Chinese Medicine广州中医药大学第三附属医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Third Affiliated Hospital of Southern Medical University南方医科大学第三附属医院 | 8 | none | none | none | none | none | none | none | none | none | none | 9 | none | none | 0 | 31 open | none | none | none | 21 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Third Affiliated Hospital of Sun Yat-sen University中山大学附属第三医院 | 10 | none | 1713 open | 15 | none | 6 | 19 | none | 1 | none | none | 2 | 0 | 1 | none | 4 | none | none | 1 | 6 | 0 | none | none | none | 1 | 392 open | none | 01 open | 3 | 0 | none | 9 | none | 4 | 22 | 2 | none | 1 | none | 2 | none | none | none | none | 0 | 1 | 0 | none | 0 | none | 2 | 1 | none | none | none | 0 | none | none | none | none | none | |
| Third People's Hospital, Guangzhou Medical University | none | none | none | none | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhongshan Ophthalmic Center中山大学中山眼科中心 | none | none | none | none | none | none | none | none | none | 251 open | none | none | none | 0 | none | none | none | none | none | 41 open | none | none | none | none | none | 4 | none | none | none | none | none | none | 8 | 1 | none | none | none | none | none | none | none | none | none | none | 7 | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | |
| Zhujiang Hospital南方医科大学珠江医院 | 11 | 4 | 545 open | 10 | 691 open | 21 | 24 | 661 open | none | 1 | 1 | 9 | none | 6 | none | 23 open | 12 open | none | none | 101 open | 1 | none | none | none | none | none | none | none | none | none | none | 7 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | 2 | none | none | none | none | none | none | 5 | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Guangzhou.
- Nasopharyngeal carcinoma 6
- Oesophageal squamous cell carcinoma 3
- Lung cancer 18621 open
- Osteosarcoma 0
- Neuroblastoma 1
- Lymphoma 1
- Congenital heart disease 2
- Anti-NMDA receptor encephalitis 0
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 21
- Lymphangioleiomyomatosis 3
- Primary biliary cholangitis 1
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 16
- Oesophageal squamous cell carcinoma 5
- Hepatocellular carcinoma 451 open
- Stomach cancer 21
- Lung cancer 59
- Breast cancer 57
- Glioma 30
- Retinoblastoma 0
- Osteosarcoma 9
- Gastrointestinal stromal tumour 1
- Neuroblastoma 2
- Multiple myeloma 5
- Lymphoma 5
- Beta thalassaemia 2
- Myasthenia gravis 4
- Wilson disease 2
- Coronary heart disease 7
- Congenital heart disease 6
- Anti-NMDA receptor encephalitis 0
- Idiopathic pulmonary fibrosis 1
- Alport syndrome 1
- IgA nephropathy 0
- Hirschsprung disease 2
- Inherited epidermolysis bullosa 2
- Nasopharyngeal carcinoma 143 open
- Oesophageal squamous cell carcinoma 201 open
- Hepatocellular carcinoma 2196 open
- Stomach cancer 52
- Lung cancer 71
- Pancreatic cancer 39
- Breast cancer 491 open
- Glioma 391 open
- Hepatoblastoma 5
- Retinoblastoma 1
- Chordoma 0
- Osteosarcoma 33
- Gastrointestinal stromal tumour 92 open
- Neuroblastoma 0
- Ewing sarcoma 1
- Multiple myeloma 18
- B-cell acute lymphoblastic leukaemia 1
- Haemophagocytic lymphohistiocytosis 2
- Lymphoma 3
- Beta thalassaemia 5
- Neuromyelitis optica spectrum disorder 2
- Myasthenia gravis 28
- Moyamoya disease 4
- Wilson disease 6
- Biliary atresia 12
- Coronary heart disease 211 open
- Congenital heart disease 61 open
- Scoliosis 5
- Anti-NMDA receptor encephalitis 2
- Takayasu arteritis 0
- Hepatic echinococcosis 1
- Idiopathic pulmonary fibrosis 9
- Amyotrophic lateral sclerosis 2
- Spinal muscular atrophy 4
- Fabry disease 0
- Pompe disease 0
- Duchenne muscular dystrophy 5
- Behçet disease 4
- Alport syndrome 0
- IgA nephropathy 222 open
- Gaucher disease 0
- Primary biliary cholangitis 1
- Primary sclerosing cholangitis 0
- Hirschsprung disease 1
- Hereditary angioedema 0
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 5
- Hepatocellular carcinoma 25
- Stomach cancer 12
- Lung cancer 41
- Pancreatic cancer 6
- Breast cancer 501 open
- Glioma 12
- Osteosarcoma 2
- Gastrointestinal stromal tumour 1
- Neuroblastoma 3
- Ewing sarcoma 1
- Beta thalassaemia 0
- Neuromyelitis optica spectrum disorder 4
- Myasthenia gravis 0
- Coronary heart disease 15
- Congenital heart disease 7
- Anti-NMDA receptor encephalitis 0
- Idiopathic pulmonary fibrosis 2
- Lymphangioleiomyomatosis 1
- Amyotrophic lateral sclerosis 4
- IgA nephropathy 6
- Primary biliary cholangitis 2
- Nasopharyngeal carcinoma 14
- Oesophageal squamous cell carcinoma 19
- Hepatocellular carcinoma 541 open
- Stomach cancer 211 open
- Lung cancer 23619 open
- Pancreatic cancer 441 open
- Breast cancer 9610 open
- Glioma 43
- Hepatoblastoma 1
- Retinoblastoma 2
- Chordoma 1
- Osteosarcoma 11
- Gastrointestinal stromal tumour 1
- Neuroblastoma 0
- Multiple myeloma 3
- B-cell acute lymphoblastic leukaemia 1
- Lymphoma 23
- Beta thalassaemia 1
- Neuromyelitis optica spectrum disorder 3
- IgG4-related disease 3
- Myasthenia gravis 1
- Coronary heart disease 652 open
- Congenital heart disease 80
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 1
- Fabry disease 1
- Behçet disease 1
- IgA nephropathy 81 open
- Primary biliary cholangitis 4
- Primary sclerosing cholangitis 1
- Nasopharyngeal carcinoma 4
- Hepatocellular carcinoma 22
- Stomach cancer 12
- Pancreatic cancer 11
- Breast cancer 20
- Osteosarcoma 4
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Multiple myeloma 0
- Aplastic anaemia 13
- Lymphoma 7
- Beta thalassaemia 1
- Thrombotic thrombocytopenic purpura 1
- Fanconi anaemia 1
- Anti-NMDA receptor encephalitis 4
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 2
- Duchenne muscular dystrophy 2
- IgA nephropathy 1
- Gaucher disease 0
- Primary biliary cholangitis 0
- Nasopharyngeal carcinoma 2
- Lung cancer 5
- Breast cancer 161 open
- Glioma 13
- Hepatoblastoma 9
- Retinoblastoma 3
- Osteosarcoma 1
- Gastrointestinal stromal tumour 0
- Neuroblastoma 321 open
- B-cell acute lymphoblastic leukaemia 21 open
- Beta thalassaemia 191 open
- Haemophilia A 0
- Neuromyelitis optica spectrum disorder 1
- Wilson disease 2
- Biliary atresia 19
- Coronary heart disease 7
- Congenital heart disease 34
- Scoliosis 2
- Anti-NMDA receptor encephalitis 3
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 0
- Pompe disease 1
- Duchenne muscular dystrophy 2
- Alport syndrome 2
- IgA nephropathy 0
- Gaucher disease 1
- Osteogenesis imperfecta 1
- Primary sclerosing cholangitis 0
- Congenital diaphragmatic hernia 11
- Hirschsprung disease 7
- Nasopharyngeal carcinoma 336 open
- Oesophageal squamous cell carcinoma 84 open
- Hepatocellular carcinoma 1277 open
- Stomach cancer 12812 open
- Lung cancer 835 open
- Pancreatic cancer 8
- Breast cancer 832 open
- Glioma 531 open
- Hepatoblastoma 0
- Retinoblastoma 0
- Osteosarcoma 6
- Gastrointestinal stromal tumour 2
- Neuroblastoma 2
- Multiple myeloma 3
- B-cell acute lymphoblastic leukaemia 8
- Lymphoma 19
- Beta thalassaemia 21
- Haemophilia A 9
- Atypical haemolytic uraemic syndrome 1
- Neuromyelitis optica spectrum disorder 3
- Myasthenia gravis 1
- Moyamoya disease 6
- Coronary heart disease 13
- Congenital heart disease 1
- Scoliosis 0
- Anti-NMDA receptor encephalitis 7
- Idiopathic pulmonary fibrosis 5
- Amyotrophic lateral sclerosis 6
- Spinal muscular atrophy 1
- Fabry disease 2
- Duchenne muscular dystrophy 0
- Alport syndrome 0
- IgA nephropathy 51 open
- Primary biliary cholangitis 1
- Congenital diaphragmatic hernia 1
- Hirschsprung disease 0
- Familial adenomatous polyposis 2
- Nasopharyngeal carcinoma 4
- Hepatocellular carcinoma 3918 open
- Stomach cancer 41 open
- Lung cancer 1315 open
- Pancreatic cancer 64 open
- Breast cancer 84 open
- Glioma 14
- Osteosarcoma 1
- Neuroblastoma 1
- Multiple myeloma 5
- B-cell acute lymphoblastic leukaemia 0
- Lymphoma 2
- Beta thalassaemia 2
- Haemophilia A 0
- Neuromyelitis optica spectrum disorder 2
- Congenital heart disease 4
- Anti-NMDA receptor encephalitis 0
- Idiopathic pulmonary fibrosis 3
- IgA nephropathy 0
- Hereditary angioedema 0
- Oesophageal squamous cell carcinoma 0
- Stomach cancer 455 open
- Pancreatic cancer 7
- Breast cancer 161 open
- Retinoblastoma 0
- Osteosarcoma 1
- Gastrointestinal stromal tumour 3
- Beta thalassaemia 1
- Behçet disease 1
- IgA nephropathy 4
- Gaucher disease 1
- Primary sclerosing cholangitis 1
- Hirschsprung disease 0
- Inherited epidermolysis bullosa 1
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 255 open
- Oesophageal squamous cell carcinoma 102 open
- Hepatocellular carcinoma 6610 open
- Stomach cancer 115 open
- Lung cancer 362 open
- Pancreatic cancer 34
- Breast cancer 13548 open
- Glioma 11
- Hepatoblastoma 2
- Osteosarcoma 6
- Gastrointestinal stromal tumour 0
- Neuroblastoma 101 open
- Ewing sarcoma 2
- Multiple myeloma 1
- B-cell acute lymphoblastic leukaemia 4
- Haemophagocytic lymphohistiocytosis 4
- Lymphoma 7
- Beta thalassaemia 6
- Neuromyelitis optica spectrum disorder 01 open
- IgG4-related disease 4
- Coronary heart disease 29
- Congenital heart disease 2
- Scoliosis 4
- Hepatic echinococcosis 1
- Amyotrophic lateral sclerosis 3
- Behçet disease 1
- IgA nephropathy 7
- Osteogenesis imperfecta 0
- Primary biliary cholangitis 0
- Primary sclerosing cholangitis 0
- Nasopharyngeal carcinoma 48357 open
- Oesophageal squamous cell carcinoma 1378 open
- Hepatocellular carcinoma 28118 open
- Stomach cancer 1034 open
- Lung cancer 35732 open
- Pancreatic cancer 553 open
- Breast cancer 22217 open
- Glioma 621 open
- Hepatoblastoma 01 open
- Chordoma 0
- Osteosarcoma 191 open
- Gastrointestinal stromal tumour 2
- Neuroblastoma 75 open
- Ewing sarcoma 31 open
- Multiple myeloma 16
- B-cell acute lymphoblastic leukaemia 3
- Haemophagocytic lymphohistiocytosis 1
- Lymphoma 14225 open
- Beta thalassaemia 1
- Fanconi anaemia 0
- Idiopathic pulmonary fibrosis 2
- Nasopharyngeal carcinoma 10
- Hepatocellular carcinoma 1713 open
- Stomach cancer 15
- Pancreatic cancer 6
- Breast cancer 19
- Hepatoblastoma 1
- Osteosarcoma 2
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Multiple myeloma 4
- Haemophagocytic lymphohistiocytosis 1
- Lymphoma 6
- Beta thalassaemia 0
- Fanconi anaemia 1
- Neuromyelitis optica spectrum disorder 392 open
- Myasthenia gravis 01 open
- Moyamoya disease 3
- Wilson disease 0
- Coronary heart disease 9
- Scoliosis 4
- Anti-NMDA receptor encephalitis 22
- Takayasu arteritis 2
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 2
- Behçet disease 0
- Alport syndrome 1
- IgA nephropathy 0
- Niemann–Pick disease type C 0
- Primary biliary cholangitis 2
- Primary sclerosing cholangitis 1
- Hereditary angioedema 0
- Nasopharyngeal carcinoma 11
- Oesophageal squamous cell carcinoma 4
- Hepatocellular carcinoma 545 open
- Stomach cancer 10
- Lung cancer 691 open
- Pancreatic cancer 21
- Breast cancer 24
- Glioma 661 open
- Retinoblastoma 1
- Chordoma 1
- Osteosarcoma 9
- Neuroblastoma 6
- Multiple myeloma 23 open
- B-cell acute lymphoblastic leukaemia 12 open
- Lymphoma 101 open
- Beta thalassaemia 1
- Coronary heart disease 7
- Amyotrophic lateral sclerosis 1
- IgA nephropathy 2
- Hirschsprung disease 5
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lung cancer.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Guangzhou on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.